Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
0.02
P/B Ratio
0.53
Industry P/E
--
Debt to Equity
--
ROE
-4.51 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-203.80 Mln
EBITDA
$-198.88 Mln
Net Profit
$-318.09 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jaguar Animal Health Inc (JAGX)
| -75.50 | -72.50 | -73.67 | 253.57 | -81.73 | -69.38 | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Jaguar Animal Health Inc (JAGX)
| 558.59 | -97.68 | -91.63 | -57.46 | 1.75 | -95.00 | -88.96 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.71 | 10,257.64 | 20.82 | 23.13 | |
| 33.86 | 13,384.89 | -- | -28.77 | |
| 109.77 | 11,042.16 | 33.66 | 14.16 | |
| 74.93 | 9,430.55 | 41.53 | 19.71 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates... through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. Address: 200 Pine Street, San Francisco, CA, United States, 94104 Read more
Founder, CEO, President & Director
Ms. Lisa A. Conte
Founder, CEO, President & Director
Ms. Lisa A. Conte
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Jaguar Animal Health Inc (JAGX) stood at $ 51 Mln as on 31-Dec-23
The share price of Jaguar Animal Health Inc (JAGX) is $0.25 (NASDAQ) as of 18-Mar-2025 15:36 EDT. Jaguar Animal Health Inc (JAGX) has given a return of -81.73% in the last 3 years.
Jaguar Animal Health Inc (JAGX) has a market capitalisation of $ 7 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Jaguar Animal Health Inc (JAGX) is 0.02 times as on 17-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jaguar Animal Health Inc (JAGX) and enter the required number of quantities and click on buy to purchase the shares of Jaguar Animal Health Inc (JAGX).
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. Address: 200 Pine Street, San Francisco, CA, United States, 94104
The CEO & director of Ms. Lisa A. Conte. is Jaguar Animal Health Inc (JAGX), and CFO & Sr. VP is Ms. Lisa A. Conte.
There is no promoter pledging in Jaguar Animal Health Inc (JAGX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Jaguar Animal Health Inc (JAGX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Jaguar Animal Health Inc (JAGX) was No Profit.
$-0.22
(
